Oncology and Hematology

Episodes 17-32 of 56

• 

  RestartResume

  Molecular Profiling as a Cornerstone of Precision AML Therapy

  RestartResume

  Molecular Profiling as a Cornerstone of Precision AML Therapy

  MinuteCE®

  Molecular Profiling as a Cornerstone of Precision AML Therapy

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Menin Inhibitors: Biologic and Clinical Rationale 

  RestartResume

  Menin Inhibitors: Biologic and Clinical Rationale 

  MinuteCE®

  Menin Inhibitors: Biologic and Clinical Rationale 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML 

  RestartResume

  Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML 

  MinuteCE®

  Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  RestartResume

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  MinuteCE®

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Managing Adverse Events Associated With Menin Inhibitors 

  RestartResume

  Managing Adverse Events Associated With Menin Inhibitors 

  MinuteCE®

  Managing Adverse Events Associated With Menin Inhibitors 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Applying Evidence to Clinical Practice 

  RestartResume

  Applying Evidence to Clinical Practice 

  MinuteCE®

  Applying Evidence to Clinical Practice 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Emerging Directions in Menin-Directed AML Therapy 

  RestartResume

  Emerging Directions in Menin-Directed AML Therapy 

  MinuteCE®

  Emerging Directions in Menin-Directed AML Therapy 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  RestartResume

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  MinuteCE®

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Expert Recommendations and Key Takeaways

  RestartResume

  Expert Recommendations and Key Takeaways

  MinuteCE®

  Expert Recommendations and Key Takeaways

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer

  RestartResume

  Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer

  CME/CE Broadcast Replay

  Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer

  1.00 credit

  • 

    

    Vallerie V. McLaughlin, MD

  • 

    

    Marsha Burks, BSN, RN

  • 

    

    Rajan Saggar, MD

  1.00 credit

• 

  MinuteCE®

  Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC

  0.75 credits 7 episodes

  • 

    

    Harry Yoon, MD

  • 

    

    Jaffer Ajani, MD

  0.75 credits 7 episodes

• 

  RestartResume

  Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies

  RestartResume

  Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies

  MinuteCE®

  Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies

  0.75 program credits

  • 

    

    Jaffer Ajani, MD

  0.75 program credits

• 

  RestartResume

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  RestartResume

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  MinuteCE®

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  0.75 program credits

  • 

    

    Harry Yoon, MD

  0.75 program credits

• 

  RestartResume

  Effective Monitoring and Management of Adverse Effects in Metastatic ESCC

  RestartResume

  Effective Monitoring and Management of Adverse Effects in Metastatic ESCC

  MinuteCE®

  Effective Monitoring and Management of Adverse Effects in Metastatic ESCC

  0.75 program credits

  • 

    

    Harry Yoon, MD

  • 

    

    Jaffer Ajani, MD

  0.75 program credits

• 

  RestartResume

  ICI Combination Regimens for First-Line Treatment of Metastatic ESCC

  RestartResume

  ICI Combination Regimens for First-Line Treatment of Metastatic ESCC

  MinuteCE®

  ICI Combination Regimens for First-Line Treatment of Metastatic ESCC

  0.75 program credits

  • 

    

    Harry Yoon, MD

  • 

    

    Jaffer Ajani, MD

  0.75 program credits

• 

  RestartResume

  Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC

  RestartResume

  Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC

  MinuteCE®

  Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC

  0.75 program credits

  • 

    

    Harry Yoon, MD

  • 

    

    Jaffer Ajani, MD

  0.75 program credits